Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS

S. P. Bathena, J. Huang, M. E. Nunn, T. Miyamoto, L. C. Parrish, M. S. Lang, T. P. McVaney, Myron Lee Toews, D. R. Cerutis, Yazen Alnouti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Lysophosphatidic acid (LPA) is a phospholipid mediator that plays multiple cellular functions by acting through G protein-coupled LPA receptors. LPAs are known to be key mediators in inflammation, and several lines of evidence suggest a role for LPAs in inflammatory periodontal diseases. A simple and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method has been developed and validated to quantify LPA species (LPA 18:0, LPA 16:0, LPA 18:1 and LPA 20:4) in human saliva and gingival crevicular fluid (GCF). LPA 17:0 was used as an internal standard and the LPA species were extracted from saliva by liquid-liquid extraction using butanol. Chromatography was performed using a Macherey-Nagel NUCLEODUR ® C8 Gravity Column (125mm×2.0mm ID) with a mixture of methanol/water: 75/25 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase A) and methanol/water: 99/0.5 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase B) at a flow rate of 0.5mL/min. LPAs were detected by a linear ion trap-triple quadrupole mass spectrometer with a total run time of 8.5min. The limit of quantification (LOQ) in saliva was 1ng/mL for all LPA species and the method was validated over the range of 1-200ng/mL. The method was validated in GCF over the ranges of 10-500ng/mL for LPA 18:0 and LPA 16:0, and 5-500ng/mL for LPA 18:1 and LPA 20:4. This sensitive LC-MS/MS assay was successfully applied to obtain quantitative data of individual LPA levels from control subjects and patients with various periodontal diseases. All four LPA species were consistently elevated in samples obtained from periodontal diseases, which supports a role of LPAs in the pathogenesis of periodontal diseases.

Original languageEnglish (US)
Pages (from-to)402-407
Number of pages6
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume56
Issue number2
DOIs
StatePublished - Sep 10 2011

Fingerprint

Gingival Crevicular Fluid
Lysophospholipids
Saliva
Fluids
formic acid
Periodontal Diseases
Methanol
Lysophosphatidic Acid Receptors
Inflammation Mediators
Butanols
Liquid-Liquid Extraction

Keywords

  • GCF
  • LC-MS/MS
  • Lysophosphatidic acid
  • Periodontitis
  • Saliva

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS. / Bathena, S. P.; Huang, J.; Nunn, M. E.; Miyamoto, T.; Parrish, L. C.; Lang, M. S.; McVaney, T. P.; Toews, Myron Lee; Cerutis, D. R.; Alnouti, Yazen.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 56, No. 2, 10.09.2011, p. 402-407.

Research output: Contribution to journalArticle

Bathena, S. P. ; Huang, J. ; Nunn, M. E. ; Miyamoto, T. ; Parrish, L. C. ; Lang, M. S. ; McVaney, T. P. ; Toews, Myron Lee ; Cerutis, D. R. ; Alnouti, Yazen. / Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS. In: Journal of Pharmaceutical and Biomedical Analysis. 2011 ; Vol. 56, No. 2. pp. 402-407.
@article{81234f2774624719a1774090a9e0de70,
title = "Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS",
abstract = "Lysophosphatidic acid (LPA) is a phospholipid mediator that plays multiple cellular functions by acting through G protein-coupled LPA receptors. LPAs are known to be key mediators in inflammation, and several lines of evidence suggest a role for LPAs in inflammatory periodontal diseases. A simple and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method has been developed and validated to quantify LPA species (LPA 18:0, LPA 16:0, LPA 18:1 and LPA 20:4) in human saliva and gingival crevicular fluid (GCF). LPA 17:0 was used as an internal standard and the LPA species were extracted from saliva by liquid-liquid extraction using butanol. Chromatography was performed using a Macherey-Nagel NUCLEODUR {\circledR} C8 Gravity Column (125mm×2.0mm ID) with a mixture of methanol/water: 75/25 (v/v) containing 0.5{\%} formic acid and 5mM ammonium formate (mobile phase A) and methanol/water: 99/0.5 (v/v) containing 0.5{\%} formic acid and 5mM ammonium formate (mobile phase B) at a flow rate of 0.5mL/min. LPAs were detected by a linear ion trap-triple quadrupole mass spectrometer with a total run time of 8.5min. The limit of quantification (LOQ) in saliva was 1ng/mL for all LPA species and the method was validated over the range of 1-200ng/mL. The method was validated in GCF over the ranges of 10-500ng/mL for LPA 18:0 and LPA 16:0, and 5-500ng/mL for LPA 18:1 and LPA 20:4. This sensitive LC-MS/MS assay was successfully applied to obtain quantitative data of individual LPA levels from control subjects and patients with various periodontal diseases. All four LPA species were consistently elevated in samples obtained from periodontal diseases, which supports a role of LPAs in the pathogenesis of periodontal diseases.",
keywords = "GCF, LC-MS/MS, Lysophosphatidic acid, Periodontitis, Saliva",
author = "Bathena, {S. P.} and J. Huang and Nunn, {M. E.} and T. Miyamoto and Parrish, {L. C.} and Lang, {M. S.} and McVaney, {T. P.} and Toews, {Myron Lee} and Cerutis, {D. R.} and Yazen Alnouti",
year = "2011",
month = "9",
day = "10",
doi = "10.1016/j.jpba.2011.05.041",
language = "English (US)",
volume = "56",
pages = "402--407",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Quantitative determination of lysophosphatidic acids (LPAs) in human saliva and gingival crevicular fluid (GCF) by LC-MS/MS

AU - Bathena, S. P.

AU - Huang, J.

AU - Nunn, M. E.

AU - Miyamoto, T.

AU - Parrish, L. C.

AU - Lang, M. S.

AU - McVaney, T. P.

AU - Toews, Myron Lee

AU - Cerutis, D. R.

AU - Alnouti, Yazen

PY - 2011/9/10

Y1 - 2011/9/10

N2 - Lysophosphatidic acid (LPA) is a phospholipid mediator that plays multiple cellular functions by acting through G protein-coupled LPA receptors. LPAs are known to be key mediators in inflammation, and several lines of evidence suggest a role for LPAs in inflammatory periodontal diseases. A simple and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method has been developed and validated to quantify LPA species (LPA 18:0, LPA 16:0, LPA 18:1 and LPA 20:4) in human saliva and gingival crevicular fluid (GCF). LPA 17:0 was used as an internal standard and the LPA species were extracted from saliva by liquid-liquid extraction using butanol. Chromatography was performed using a Macherey-Nagel NUCLEODUR ® C8 Gravity Column (125mm×2.0mm ID) with a mixture of methanol/water: 75/25 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase A) and methanol/water: 99/0.5 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase B) at a flow rate of 0.5mL/min. LPAs were detected by a linear ion trap-triple quadrupole mass spectrometer with a total run time of 8.5min. The limit of quantification (LOQ) in saliva was 1ng/mL for all LPA species and the method was validated over the range of 1-200ng/mL. The method was validated in GCF over the ranges of 10-500ng/mL for LPA 18:0 and LPA 16:0, and 5-500ng/mL for LPA 18:1 and LPA 20:4. This sensitive LC-MS/MS assay was successfully applied to obtain quantitative data of individual LPA levels from control subjects and patients with various periodontal diseases. All four LPA species were consistently elevated in samples obtained from periodontal diseases, which supports a role of LPAs in the pathogenesis of periodontal diseases.

AB - Lysophosphatidic acid (LPA) is a phospholipid mediator that plays multiple cellular functions by acting through G protein-coupled LPA receptors. LPAs are known to be key mediators in inflammation, and several lines of evidence suggest a role for LPAs in inflammatory periodontal diseases. A simple and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method has been developed and validated to quantify LPA species (LPA 18:0, LPA 16:0, LPA 18:1 and LPA 20:4) in human saliva and gingival crevicular fluid (GCF). LPA 17:0 was used as an internal standard and the LPA species were extracted from saliva by liquid-liquid extraction using butanol. Chromatography was performed using a Macherey-Nagel NUCLEODUR ® C8 Gravity Column (125mm×2.0mm ID) with a mixture of methanol/water: 75/25 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase A) and methanol/water: 99/0.5 (v/v) containing 0.5% formic acid and 5mM ammonium formate (mobile phase B) at a flow rate of 0.5mL/min. LPAs were detected by a linear ion trap-triple quadrupole mass spectrometer with a total run time of 8.5min. The limit of quantification (LOQ) in saliva was 1ng/mL for all LPA species and the method was validated over the range of 1-200ng/mL. The method was validated in GCF over the ranges of 10-500ng/mL for LPA 18:0 and LPA 16:0, and 5-500ng/mL for LPA 18:1 and LPA 20:4. This sensitive LC-MS/MS assay was successfully applied to obtain quantitative data of individual LPA levels from control subjects and patients with various periodontal diseases. All four LPA species were consistently elevated in samples obtained from periodontal diseases, which supports a role of LPAs in the pathogenesis of periodontal diseases.

KW - GCF

KW - LC-MS/MS

KW - Lysophosphatidic acid

KW - Periodontitis

KW - Saliva

UR - http://www.scopus.com/inward/record.url?scp=79960037876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960037876&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2011.05.041

DO - 10.1016/j.jpba.2011.05.041

M3 - Article

C2 - 21703797

AN - SCOPUS:79960037876

VL - 56

SP - 402

EP - 407

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 2

ER -